ImmuCell Corporation (ICCC) exhibits 41.4% gross margins and 4.2% return on invested capital within Health Care (Biotechnology: In Vitro & In Vivo Diagnostic Substances), balanced against a 35.9x enterprise multiple and 4.8% implied options volatility.
Sustained 41.4% gross profitability converts into 6.0% operating margin and 4.2% ROIC, outpacing sector cost of capital.
ROIC: 4.2% // GM: 41.4%YoY revenue trajectory of +4.3% paired with 1.31% free cash flow yield supports self-funded R&D and capital return.
REV YOY: +4.3% // FCF YLD: 1.31%Altman Z-Score of 4.28 and Piotroski F-Score of 8/9 indicate low near-term refinancing stress.
ALTMAN Z: 4.28 // F-SCORE: 8/9Trading at 24.0x trailing P/E (— Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 24.0x // EV/EBITDA: 35.9xOptions market prices a ±5.2% implied move with a 0.85 put/call ratio around $10.32 max pain.
IMPL MOVE: ±5.2% // P/C: 0.85Elevated industry capital intensity and customer concentration in Biotechnology: In Vitro & In Vivo Diagnostic Substances require continuous execution to defend -3.8% net margins.
NET MARGIN: -3.8% // D/E: 0.28x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for ICCC & activate live FRED threshold breach alerts.